A 16-week randomized trial found combined training lowered GLP-1 and amylin and raised DPP-4 in adults with type 2 diabetes and overweight, without a demonstrated glycaemic benefit. PICO summary and expert commentary.
Browsing: PICO
Structured PICO summaries for doctors and healthcare professionals, covering population, intervention, comparison, outcomes, expert commentary, and references across diabetes, endocrinology, obesity, and cardiometabolic medicine.
A randomized trial testing whether a patient previsit activation handout, added to physician academic detailing, increases diabetes medication deprescribing in adults 75 and older. PICO summary and expert commentary.
A phase 1, double-blind, placebo-controlled study of titrated noiiglutide (SHR20004) in obese Chinese adults without diabetes reported good tolerability and dose-related weight loss, with PICO summary and expert commentary.
A 26-week double-blind randomised trial testing once-weekly semaglutide added to automated insulin delivery in 72 adults with type 1 diabetes and obesity. PICO summary and expert commentary.
A first-in-human phase 1 trial of oral amycretin in overweight or obesity found it safe and tolerable, with dose-dependent gastrointestinal effects and exploratory weight loss. PICO summary and expert commentary.
Post hoc analysis of three randomised trials showing semaglutide produces similar weight loss in MASLD and MASH regardless of type 2 diabetes status or cardiometabolic risk. PICO summary and expert commentary.
An exploratory open-label RCT found imeglimin and metformin lowered HbA1c similarly, but only imeglimin raised insulin and GIP secretion. PICO summary and expert commentary.
A secondary analysis of a metformin-versus-insulin gestational diabetes trial found cord serum lipids associated with offspring beta-cell function at age nine. PICO summary and expert commentary.
A secondary analysis of a weight-loss-maintenance RCT found that low-calorie-diet weight loss raised serum 25(OH)D in both sexes, but further loss and low baseline vitamin D tracked with maintenance only in women. PICO summary and expert commentary.
A FOURIER subgroup analysis of 197 participants asks whether evolocumab cuts cardiovascular events in type 1 diabetes with established ASCVD. PICO summary and expert commentary.